Newsroom

Students of the Master’s in Neurosciences celebrated their graduation on June 20th, marking the end of a year filled with challenges and valuable learning experiences.

The first edition of the advanced in vivo calcium imaging workshop using Miniscopes took place at the Institute from June 10 to 12. This intensive course, organized by AnderoLab, equipped participants with essential skills to study neuronal activity in freely moving rodents.

The Catalan Society of Neurology has honoured Dr. Xavier Navarro Acebes for his outstanding professional and academic career with the 2025 Eduard Bertran i Rubio Award.

A study by the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) reveals that inflammation associated with Marfan syndrome increases vulnerability to neurological diseases and complications following strokes, as demonstrated in animal models.

An international study led by the Institut de Neurociències at the UAB (INc-UAB) has shown that increasing levels of the Klotho protein in mice extends lifespan and improves both physical and cognitive health when aging.

A collaborative study involving the Universitat Autònoma de Barcelona (UAB) has shown that the molecule MP-010 can enhance motor function and extend lifespan in a mouse model of Amyotrophic Lateral Sclerosis (ALS), a severe neurodegenerative disease for which there are currently no effective treatments.

The Neurotalent Games, organized by the Rosa M. Vivar Foundation with the collaboration of the INc-UAB, returned for its third edition to promote cognitive health and the prevention of neurocognitive diseases.

"In this thesis, we focused on one of the most representative forms of motor control: reaching and grasping".

After two successful terms under the leadership of Dr. Jesús Giraldo, the Institute enters a new chapter with changes in its management team. Dr. Carles Saura steps into the role of director, with Dr. Gemma Guillazo Blanch joining as deputy director.

According to a study led by Dr. Raül Andero, the drug Osanetant could reduce the intensity at which the fear memory is consolidated, thus preventing the onset of post-traumatic stress disorder (PTSD). The research, conducted with female mice, highlights important sex differences in fear processing.